Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga(Mass General Brigham), Ian Bradbury(Queen's University Belfast), Holger Eidtmann, Serena Di Cosimo(Vall d'Hebron Hospital Universitari), Evandro de Azambuja, Claudia Aura(Vall d'Hebron Institute of Oncology), Henry Gómez(Instituto Nacional de Enfermedades Neoplásicas), Phuong Dinh(Breast International Group), Karine Fauria, Veerle Van Dooren, Gursel Aktan(GlaxoSmithKline (United States)), Aron Goldhirsch(European Institute of Oncology), Tsai-Wang Chang(National Cheng Kung University Hospital), Zsolt Horváth(National Institute of Oncology), M.A. Coccia-Portugal, Julien Dômont(Institut Gustave Roussy), Ling-Min Tseng(National Yang Ming Chiao Tung University), Georg Kunz(St.-Johannes-Hospital Dortmund), Joohyuk Sohn(Yonsei University), Semiglazov Vf(Institute of Oncology NN Petrov), Guillermo Lerzo, Markéta Palácová(Masaryk University), Volodymyr Probachai(Regional Clinical Hospital named after II Mechnikov), Lajos Pusztai(The University of Texas MD Anderson Cancer Center), Michael Untch(Charité - Universitätsmedizin Berlin), Richard D. Gelber(Dana-Farber Cancer Institute), Martine Piccart(Institut Jules Bordet)
Cited by 1,312Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis